



The 65-Point Verification Standard.

Current scope and evidence edition · products and facilities

65

NUMBERED
CHECKPOINTS

2

VISITOR ROUTES

7

MARKET ANNEXES

Record the work. State its limits.

This edition replaces v3.1 as the current public service checklist. Each engagement records which points apply, which are outside scope, and why. It is not a promise that all 65 activities are performed on every engagement.

Products: agreed production observations and controlled sealing of identified packaging. Facilities: dated visits to agreed areas, with supplied information attributed. Laboratory testing is optional, independently provided and separately charged.

What this edition does not activate

It does not change the production registry, introduce a new badge cycle or approve automatic release, withdrawal or disposal. Where a rule or software limitation is unresolved, the affected public claim or issuance must wait for written resolution. Reports may accurately describe completed observations without claiming an unavailable status.

Observed activity. Identified packaging. Attributed evidence.

This document is a service-scope checklist, not a verification report, accreditation, regulatory approval or guarantee of quality, safety, efficacy, treatment outcomes or future conditions. Existing signed terms retain their agreed precedence.



How to apply the checklist.

Agree applicability before attendance.

Record the client's question, site, production activity or facility areas, access, deliverables and evidence requirements. Mark every point applicable, not requested, not relevant or not established, with a reason. Do not turn an unperformed check into a pass.

EVIDENCE ATTRIBUTION

Observed: what TG directly saw, with date and scope. **Presented:** information supplied by an identified source. **Independently confirmed:** the specific fact checked, external source, method and date. A public-register check is one form of confirmation; it is not regulatory endorsement.

Table labels identify the type of evidence to record, not a completed outcome. Mixed-source points must distinguish each source in the report.

Independence and commissioning

Buyers, producers, facility operators and service partners may commission TG, including for their own premises or production batch. Fees pay for agreed work, not a favourable finding. TG accepts no referral commission or influence payment, and does not manufacture, sell, select suppliers or perform laboratory analysis.

Engagement sequence

Enquiry and scope review come first, followed by written quotation. Payment and authorisation precede agreed access-check activity. Submission alone does not authorise site contact. If the full engagement proceeds, the access-check fee is credited against it. Refusal and any reason supplied are reported; refusal alone is not wrongdoing.

Optional work and release boundaries

Sampling and Section D apply only where requested and agreed. No laboratory report recorded is distinct from an adverse result. Full reports and authorised public summaries are separate; disclosure needs relevant permission. The fictional public-summary demonstrations are proposed presentation, not evidence that all features exist in the live registry.

Facility scope

Individuals, including prospective guests and patients, may enquire about scoped factual visits. TG does not give treatment advice, assess clinical competence or audit professional qualifications. Manufacturing medical devices belongs in the product route; visiting a place using them belongs in the facility route.

Checkboxes record review completion only. Record applicability, evidence and limitations separately; a tick is not a pass or certification.



One framework. Seven markets.

Annexes guide the subject of the agreed work. They do not impose a universal laboratory panel or automatic entitlement to a seal or badge.

ANNEX MARKET AND SCOPE

P	Peptides, APIs & Compounds Agreed production and package observations. Optional laboratory scope is chosen with the independent laboratory; TG does not take custody of peptide samples.
N	Nutraceuticals, Supplements & Traditional Medicine Production and packaging observations; optional sample identity, assay, content or contaminant evidence where requested.
C	Cosmetics & Topicals Production and packaging observations; supplied records and optional sample tests with stated method and scope limits.
F	Premium Foods & Beverages Agreed production, pressing, filling or bottling activity; optional sample-linked composition or authenticity evidence.
D	Medical Devices, Equipment & Supplies Manufactured-product and packaging traceability. Supplied registration, quality, calibration or test documents are attributed; receipt is not a compliance or device-safety assessment.
H	Hospitals & Healthcare Facilities Agreed accessible areas, visible equipment and activities, and attributed operator documents. No clinical approval, sterilisation-effectiveness audit or emergency-readiness assessment.
W	Wellness, Longevity Centres, Medispas & Retreats Agreed accommodation, activity spaces and amenities, with supplied profiles and procedure records attributed. No qualification audit, calibration test or protocol-compliance guarantee.

FACILITY USE OF POINTS 16-32

Map the agreed facility observations to the relevant evidence headings and record manufacturing-only points as not relevant. Do not invent a clinical audit in their place. Sections C and D are not presumed for a facility visit.

Any optional test method, accreditation claim or comparison specification must be agreed for the actual sample and laboratory. Historical method lists in v3.1 do not create a mandatory current panel.



A · Counterparty & documents

POINTS 1-15

Record identity, authority, relevant documents and precisely scoped external checks. An unresolved legal-access or required-licence question must be resolved before affected attendance; TG does not substitute for a regulator.

01	Identify the contracting entity and its public registration number; record the register, date and any mismatch.	SOURCE CHECK
02	Record the registered business scope relevant to the requested activity. Identify production, sales and intermediary roles separately.	SOURCE CHECK
03	Compare the named site, relevant licence holder and any supplied GMP certificate holder. Explain relationships or discrepancies; do not assume they must be the same entity.	ATTRIBUTE SOURCES
04	Where a production licence is applicable, record the licence presented and the agreed check of its current public listing. TG does not determine regulatory fitness.	ATTRIBUTE SOURCES
05	If a GMP claim is relevant, identify the certificate, issuer, scope and available confirmation. A supplied document alone is presented evidence.	ATTRIBUTE SOURCES
06	Where ISO or laboratory-accreditation claims are relied on, record the certificate scope and available issuer confirmation; do not assume all sites require these certificates.	ATTRIBUTE SOURCES
07	Record the dated enterprise-credit search and any relevant abnormal-operation or violation entries found, with source and search limitations.	SOURCE CHECK
08	Record any agreed search of relevant product or facility registration listings. Distinguish a listing from approval of this engagement or product use.	SOURCE CHECK
09	If relevant to scope, record registered capital and supplied paid-in information by source; do not infer operational capability from capital alone.	ATTRIBUTE SOURCES
10	Compare the registered or licensed address with the location to be visited; record differences and explanations.	ATTRIBUTE SOURCES
11	Where export capability is claimed and within scope, identify supplied export documents and any available registration checks.	ATTRIBUTE SOURCES
12	Record relevant enforcement, penalty or litigation search results, sources, dates and coverage limits; absence of a result is not a clean-history guarantee.	SOURCE CHECK
13	Record the counterparty's signed disclosure of its role and any intermediary or subcontracting arrangements.	PRESENTED
14	Where an intermediary is involved, identify the actual site and relevant operator; obtain access authorisation or report that access could not be arranged.	ATTRIBUTE SOURCES
15	Where agreed, record sanctions or denied-party screening scope, sources, date and potential matches for qualified review; do not infer universal legal clearance.	SOURCE CHECK



B · Site & observed activity

POINTS 16–32

Describe the agreed areas and activity on the visit date. Presented records are not proof of effective systems or future conditions.

16	Obtain access confirmation identifying the site, observer, agreed areas and attendance date; record the authorising party.	PRESENTED
17	Record the opening meeting, agreed scope and attendance times. State that TG observes and reports rather than providing operational or clinical advice.	OBSERVED
18	Record the agreed areas and production activity attended, and any disclosed off-site activity or subcontracting. Do not claim unseen areas were checked.	ATTRIBUTE SOURCES
19	Compare visible equipment identifiers with the equipment records supplied, within scope. This is not a functionality or calibration test.	ATTRIBUTE SOURCES
20	Where relevant, record clean-room certificates, pressure or filter logs as supplied, including dates and gaps; do not certify their adequacy or current performance.	PRESENTED
21	Where relevant, record supplied water-system validation and monitoring documents. Receipt does not independently establish validation or water quality.	PRESENTED
22	Where relevant, record supplied HVAC qualification or maintenance documents and their stated scope.	PRESENTED
23	Describe line-clearance activity actually observed for the specified production activity, including interruptions or areas not visible.	OBSERVED
24	Identify the production-batch record presented, its dates and apparent omissions. Do not assert that its entries were contemporaneous unless independently established.	PRESENTED
25	Describe weighing, dispensing or second-person checks actually observed, with the applicable activity and time.	OBSERVED
26	Identify in-process control records supplied for the production batch; distinguish recorded results from controls TG directly witnessed.	PRESENTED
27	Record deviation and corrective-action documents supplied and any gaps relevant to the agreed work; receipt is not an effectiveness audit.	PRESENTED
28	Record change-control procedures and examples supplied; do not infer that the entire system is operating effectively.	PRESENTED
29	Record relevant raw-material supplier information and qualification documents supplied, with source and coverage limitations.	PRESENTED
30	Where relevant, identify the supplied stability programme or reports and their stated product and period. TG does not validate stability.	PRESENTED
31	Where relevant, record environmental or pest-monitoring documents supplied and activities actually observed, distinguishing each source.	ATTRIBUTE SOURCES
32	Describe segregation and cross-contamination precautions actually observed in the agreed areas; this is not a guarantee of their effectiveness or future operation.	OBSERVED



C · Packaging & optional samples

POINTS 33–44

Sampling and transport points are conditional on requested testing. Exact assigned packaging defines seal coverage; optional sampling must remain distinct from that manifest.

33	If sampling is requested, record the client/laboratory sample plan before attendance: selection responsibility, quantities, timing, retention and limits. No universal TG sampling plan is presumed.	PRESENTED
34	Where sample selection is witnessed, identify who selected each sample, from which production batch and at what stage. Record whether TG observed selection or relied on supplied information.	ATTRIBUTE SOURCES
35	If blind coding is requested, agree responsibilities and the code key, and record the coding witnessed. Do not promise the laboratory cannot discover the sample source.	ATTRIBUTE SOURCES
36	Observe agreed tamper-evident sealing of identified packages. Manual or machine application by TG or factory staff is acceptable only within agreed TG observation and control.	OBSERVED
37	Record every applied package serial in the exact manifest and reconcile issued, applied, voided, damaged and outstanding stock. Do not define future coverage by a sequential range.	TG RECORD
38	Complete the observation and handling record with the responsible site signatory, date, time and location; signatures do not imply TG takes physical custody.	TG RECORD
39	For optional testing, the factory dispatches samples on the client's instructions. TG may coordinate instructions and document dispatch; TG does not take possession of peptide samples.	ATTRIBUTE SOURCES
40	Where a temperature logger or transit control is requested, record who placed it and the evidence available. Transport remains with the client, factory and carrier as agreed.	ATTRIBUTE SOURCES
41	For requested testing, record the laboratory's stated sample-quantity requirements and any agreed retained samples; confirm supplied or observed quantities by source.	ATTRIBUTE SOURCES
42	If samples are retained, record who holds them, their identifiers, agreed conditions and retention instructions. Do not imply TG holds peptide samples.	ATTRIBUTE SOURCES
43	Record agreed dispatch packaging, identifiers and manifest. If blind dispatch is requested, record its actual scope and any limits or departures.	ATTRIBUTE SOURCES
44	Record laboratory receipt information and any packaging discrepancy. Hold conclusions about affected sample evidence for review; do not treat that sample result as representative without resolution.	PRESENTED



D · Optional laboratory evidence

POINTS 45–56

The laboratory performs and reports the tests. TG may coordinate instructions and document the evidence relationship. None of these points makes laboratory PASS a condition of completing an observation/sealing engagement.

45	If testing is requested, record the laboratory and evidence of competence or accreditation for the selected methods where relevant. A recommendation alone is not verification of suitability.	ATTRIBUTE SOURCES
46	The client selects an independent laboratory or requests recommendations. Record the selection, independence information and separately charged laboratory arrangement.	TG RECORD
47	Record the tests, samples, relevant production batch, specification and limits agreed by the client and laboratory; list exclusions, including any supplied diluent not tested.	PRESENTED
48	Where identity testing is requested, record the selected method and report's sample identity. Additional unknown-substance screening requires an agreed scope.	PRESENTED
49	Where purity, assay or content testing is requested, preserve the report's methods, tables, units and qualifiers. Purity does not establish net content; record counter-ion corrections only where reported.	PRESENTED
50	Where endotoxin testing is requested, record the laboratory method, sample and result limits. TG does not determine suitability for injection or medical use.	PRESENTED
51	Where metals testing is requested, record the selected analytes, method, units and agreed comparison specification.	PRESENTED
52	Where residual-solvent testing is requested, record the analytes, method and limits actually reported; do not infer unperformed tests.	PRESENTED
53	Where microbial or sterility testing is requested, distinguish the tests and reported limits. Microbial limits do not establish sterility.	PRESENTED
54	Where food or oil authenticity testing is requested, identify the selected profiles or markers and the laboratory's stated interpretation and limitations.	PRESENTED
55	Where label-claim or net-content testing is requested, identify the claim, sample and agreed method; do not imply every package was tested.	PRESENTED
56	Preserve the independent laboratory report separately, exactly as issued. Link its identified sample to the relevant production batch only on documented evidence; state uncertain linkage explicitly.	ATTRIBUTE SOURCES

Samples, packages and records.

Keep four identities separate.

The manufacturer's production-batch ID, TG observation reference, package serial and laboratory sample ID identify different things. Document their relationships; matching text alone is not sufficient evidence.

Laboratory workflow

The client selects a laboratory or requests recommendations, then agrees methods, sample plan and charges with it. A recommendation does not guarantee accreditation, competence or suitability. The factory dispatches samples on client instructions; TG may coordinate those instructions and document what it actually observes. TG does not take physical custody of peptide samples.

The independent laboratory issues its own report. A later report may be linked when its source and sample-to-batch relationship are documented. It does not imply every sealed package was tested. Uncertain linkage remains uncertain; laboratory results must not be rewritten as TG conclusions.

Blind testing, when requested

Blind coding is an optional arrangement, not an absolute guarantee that a laboratory cannot learn the source. Record the agreed disclosure, code control and any limitations. Do not promise a universal sampling plan or undisclosed laboratory partnership.

Exact package coverage

Manual or machine sealing may occur under agreed TG observation and control. The exact assigned package list defines coverage. Preserve legacy serials and URLs; future identifier design is a separate implementation decision, not a sequential-range promise in this Standard.

Confidentiality and public access

Site identities, workpapers and full reports are disclosed only as authorised by the engagement and applicable obligations. A public summary contains only approved fields. Report requests do not themselves grant permission. Existing signed confidentiality protections are not waived by this edition.

Current capability versus proposed experience

The existing product registry has legacy statuses and behaviour. This edition does not assert that those have been redesigned. Facility summaries and richer evidence-link displays shown in demonstrations remain illustrative unless explicitly provided in an issued record. Do not change a legacy status merely to imitate a demonstration.



E · Review & release

POINTS 57–65

57	Reconcile workpapers, dates, observation times, photographs where authorised, supplied documents and handling records. State missing evidence and access limits.	TG RECORD
58	Maintain an exceptions log with evidence, source, timing, affected scope and the counterparty's response. Identify unresolved concerns without turning missing information into an allegation.	TG RECORD
59	Escalate material exceptions for written review before affected claims or marks are issued: lost observation continuity, unestablished sample origin, damaged receipt packaging, unexplained entity or batch mismatch, refused control, or improper payment requests. A pre-dated certificate needs context; absent optional testing alone is not an adverse result.	TG RECORD
60	Draft findings for the agreed observation and package scope, separating laboratory evidence and unresolved issues. Do not force all findings into an unconditional batch-wide VERIFIED/WITHDRAWN conclusion.	TG RECORD
61	Obtain Managing Director review of the report, manifest, evidence limitations, proposed disclosure and unresolved exceptions. Any applicable adverse-result or eligibility rule must be identified, not invented.	TG RECORD
62	Record approval, signature, version and issue date. Record a document hash where generated, but do not describe it as blockchain anchoring or immutable storage.	TG RECORD
63	Reconcile exact package assignments and every issued seal before release. Investigate outstanding or mismatched stock; do not silently extend coverage to unassigned packages.	TG RECORD
64	Use only the actual supported registry workflow and authorised record fields. An observation/seal engagement does not require laboratory PASS. If a legacy workflow cannot represent it accurately, hold affected registry issuance and resolve the limitation; do not mislabel the result or claim software was changed.	TG RECORD
65	Release the approved report to the client with disclosure limits. Retain engagement records under the current Privacy Policy. Any facility badge separately requires defined eligibility, review and publication permission; a visit or report alone does not confer one.	TG RECORD

UNRESOLVED RULES ARE NOT APPROVALS

Badge eligibility/validity, adverse-result handling and new registry status transitions require explicit applicable rules. Hold the affected claim or mark pending written resolution. This edition neither silently waives an existing agreed obligation nor invents an automatic withdrawal or favourable outcome.



Use the current record.

Current edition: v3.2 · 30 September 2026. The 23 September 2026 v3.1 issue is historical and retained for reference.

What changed from v3.1

- Applicability is recorded for all 65 points; optional sampling and testing are not compulsory engagement gates.
- Client-selected laboratories, factory dispatch and sample-specific evidence replace universal blind-panel claims.
- Exact package assignments and observed control replace range-based coverage and unconditional batch-wide status promises.
- Commissioning includes producers, operators and service partners; fees remain independent of findings.
- Facility language records scoped observations and attributed documents, without clinical, qualification or automatic-badge claims.
- Current registry constraints and unresolved eligibility/adverse-result rules are explicit. No software or production record is changed by this document.

Explore the two routes

Products & Production

tekmerisglobal.com/resources/batch-verification-guide/

Facilities & Places

tekmerisglobal.com/facilities/

Current Standard and historical issue

tekmerisglobal.com/the-standard/

Start an enquiry

Production: tekmerisglobal.com/intake/

Facility or individual enquiry: tekmerisglobal.com/contact/

© 2026 TEKMERIS Global. All rights reserved. TG does not manufacture, buy, sell, import, export, broker or distribute products; select suppliers; certify or accredit facilities; or determine regulatory fitness. A product labelled research use only is not for human or animal use. Nothing here is medical or legal advice. Mandatory legal rights and signed engagement terms are not removed. This Standard is not itself evidence about a particular product or facility.